

### 35-1358: Beta-catenin (Phospho-Ser715) Antibody

<b>Clonality :</b>	Polyclonal
<b>Application :</b>	IHC,WB
<b>Reactivity :</b>	Rat,Mouse,Human
<b>Gene :</b>	CTNNB1
<b>Gene ID :</b>	1499
<b>Uniprot ID :</b>	P35222
<b>Alternative Name :</b>	Catenin beta-1; CTNB1; CTNNB; CTNNB1
<b>Immunogen Information :</b>	Peptide sequence around phosphorylation site of serine 715 (D-P-S(p)-Y-R) derived from Human beta-catenin.

#### Description

Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML

**Modification:** Phospho-Ser715

#### Product Info

<b>Amount :</b>	50 µg / 100 µl
<b>Purification :</b>	Affinity-chromatography
<b>Content :</b>	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg <sup>2+</sup> and Ca <sup>2+</sup> ), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
<b>Storage condition :</b>	Store at 4°C; For long-term storage; store at -20°C. Avoid repeated freeze and thaw cycles.

#### Application Note

Western blotting: 1:500~1:1000




Figure 1: Immunohistochemical analysis of paraffin-embedded human primary glioblastoma multiforme (GBM) specimens using beta-catenin (Phospho-Ser715) Antibody 35-1358 .




Figure 2: Western blot analysis of extract from U87 cells transfected with either PKCδ siRNA targeting or control siRNA were treated with Wnt3a (100 ng ml<sup>-1</sup>) for 8 h. WB was performed with nuclearlysates of the cells with the beta-catenin (Phospho-Ser715) Antibody 35-1358 .